AR and posterior cortical atrophy: Their study improved the molecular classification of PCa relevant to therapy and hypothesized that the AVPC-I and AVPC-M subtypes are resistant to androgen receptor signaling inhibitors (ARSIs) and have low prostate-specific antigen (PSA) levels.